Valsartan Recall Expands: Mylan Recalls Over 100 Lots

Pharmaceutical company Mylan is recalling some of its blood pressure medications due to cancer concerns. The medications recalled all contain Valsartan. Since July 2018, the FDA has been recalling Valsartan due to finding trace amounts of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), which are classified as probable human carcinogens by the Environmental Protection Agency.

Mylan has recalled a total of 119 lots of medication containing Valsartan, including Amlodipine and Valsartan Tablets, Valsartan Tablets, and Hydrochlorothiazide Tablets. The list of all recalled lots can be found here.

This is the largest recall in FDA history. Mylan joins a growing number of companies that have recalled lots that contain Valsartan, Irbesartan, and Losartan due to carcinogen contamination. GoldenbergLaw is committed to holding these pharmaceutical companies accountable. If you or a loved one has taken Valsartan, Irbesartan, or Losartan and have been diagnosed with cancer, contact GoldenbergLaw.